RxDoctor Payments Data

Jonathan Gaspar, MD

Gastroenterology · Mechanicsville, VANPI 1174744429

Payments from drug & device makers

$10,453in general payments, 2019–2025

Across 518 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$861
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$794
  • Sanofi$472
  • Pfizer$394
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$10,453100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,453 in reported general payments places this provider in the 70th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$102,201
Medicare patients
429
Services billed
682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$335,785
CreonLipase/Protease/Amylase53$231,233
Humira(Cf) PenAdalimumab16$113,669
ZenpepLipase/Protease/Amylase11$29,207
LinzessLinaclotide19$28,534
Mesalamine16$14,194
Pantoprazole Sodium300$4,600
Colestipol Hcl35$4,155
Dexlansoprazole DrDexlansoprazole12$3,497
Omeprazole157$2,720
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl150$2,128
Dicyclomine Hcl18$866
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates12$837
Lansoprazole16$805
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl42$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,128$335,78512 claims
AbbVieCreon, Linzess$4,080$259,76772 claims
Aimmune Therapeutics, Inc.Zenpep$65$29,20711 claims
SandozLansoprazole$23$80516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →